NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Nuvectis Pharma, Inc. (NVCT) Stock Analysis

Nuvectis Pharma, Inc. (NVCT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NVCT

$20.70

+$0.11 (+0.53%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NVCT with… →

NVCT Key Statistics

As of Oct 21, 2026
Trading
Open
$20.63
Previous Close
$20.59
Day's Range
19.94–21.72
52-Week Range
5.55–29.28
Volume
203.58K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.24
Valuation
Market Cap
$675.73M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.31
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$26.44M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
32.64M
1-Year Return
+243.85%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
206.64K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NVCT closed at $20.70, +243.85% over 1 year.

Nuvectis Pharma, Inc. (NVCT) has a market capitalization of $675.73M.

In fiscal 2025, NVCT reported revenue of $0.00.

NVCT Stock Return by Calendar Year

Nuvectis Pharma, Inc. (NVCT) return since Feb 2022: what $10,000 became

1 year
$10,000 $34,385
+243.85%
3 years
$10,000 $22,524
+125.24%
Since Feb 2022
$10,000 $63,692
+536.92%

If you had invested $10,000 in Nuvectis Pharma, Inc. (NVCT) at the close on February 4, 2022, the earliest close on record here, it would have been worth $63,692 at the close on October 21, 2026: +536.92% in total, +48.17% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+174.17%
2025+39.56%
2024−35.13%
2023+11.20%
2022 (partial year)+130.77%

As of October 21, 2026.

NVCT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$26.44M—
2024$0.00−$19.00M—
2023$0.00−$22.26M—
2022$0.00−$19.09M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$27.57M−$26.44M—
2024$0.00—−$19.85M−$19.00M—
2023$0.00—−$22.90M−$22.26M—
2022$0.00—−$19.23M−$19.09M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Nuvectis Pharma, Inc. (NVCT) is capitalised at $675.73M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 16.

The most recent close on file for NVCT is $20.70, dated October 21, 2026. That is +$0.11 (+0.53%) against the previous close. The 52-week range on file runs from $5.55 to $29.28. The latest close sits 272.97% above that 52-week low.

Financial Health

In fiscal 2025, Nuvectis Pharma, Inc. reported revenue of $0.00. The same year closed with a net loss of $26.44M. Trailing earnings per share are −1.31.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is +243.85%. Across 3 years the annualized return works out at +31.08%. The reported beta is −0.24. Daily returns over the trailing 4 years annualize to a volatility of 81.66%.

Growth & Income

The record shows no dividend for NVCT.

2026 is still running; the total return is +174.17% year to date. The strongest complete calendar year on file is 2025 at +39.56%; the weakest is 2024 at −35.13%. Of the 3 complete calendar years on file, 2 finished higher.

Peer Comparison

Nuvectis Pharma, Inc. (NVCT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Nuvectis Pharma, Inc. NVCT $675.73M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Nuvectis Pharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Visit website →